期刊
CELLULAR & MOLECULAR IMMUNOLOGY
卷 16, 期 1, 页码 40-52出版社
CHIN SOCIETY IMMUNOLOGY
DOI: 10.1038/s41423-018-0168-y
关键词
PVR; tumor; immunotherapy; checkpoint; TIGIT; poliovirus
类别
资金
- grant Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology [KK.01.1.1.01.0006]
- Croatian Science Foundation (HRZZ) [1533]
- European Regional Development Fund
Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions. In contrast to healthy tissues, PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy. More intriguingly, PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors. These functions are often modified in the tumor microenvironment, contributing to tumor immunosuppression. Indeed, increasing evidence supports the rationale for developing strategies targeting these interactions, either in terms of checkpoint therapy (i.e., targeting inhibitory receptors) or in adoptive cell therapy, which targets PVR as a tumor marker.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据